Literature DB >> 15929452

Disseminated intravascular coagulation: treat the cause, not the lab values.

Carrie Ann Labelle1, Craig S Kitchens.   

Abstract

Disseminated intravascular coagulation (DIC) is a manifestation of an underlying pathologic process such as cancer, infection, trauma, or obstetric catastrophe. It can manifest as thrombosis, bleeding, or both. To succeed, treatment must address the underlying cause.

Entities:  

Mesh：

Year:  2005        PMID： 15929452     DOI： 10.3949/ccjm.72.5.377

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  6 in total

1.  Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.

Authors:  Kazuo Tamura; Hidehiko Saito; Hidesaku Asakura; Kohji Okamoto; Jun Tagawa; Toru Hayakawa; Nobuo Aoki
Journal:  Int J Clin Oncol       Date:  2014-11-12       Impact factor: 3.402

2.  Blood Component Utilization for Disseminated Intravascular Coagulation (DIC) Cases with Respect to Underlying Condition.

Authors:  Snehalata C Gupte; Abhay G Jhaveri
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-25       Impact factor: 0.900

3.  Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis.

Authors:  Mónica Palma Anselmo; Gustavo Nobre de Jesus; João Madeira Lopes; Rui M M Victorino; João Meneses Santos
Journal:  Case Rep Hematol       Date:  2016-10-10

Review 4.  Understanding and treating solid tumor-related disseminated intravascular coagulation in the "era" of targeted cancer therapies.

Authors:  Felice Vito Vitale; Giuseppe Sa Longo-Sorbello; Stefano Rotondo; Francesco Ferrau
Journal:  SAGE Open Med       Date:  2017-12-21

5.  Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.

Authors:  Kota Ouchi; Shin Takahashi; Sonoko Chikamatsu; Shukuei Ito; Yoshikazu Takahashi; Sadayuki Kawai; Akira Okita; Yuki Kasahara; Yoshinari Okada; Hiroo Imai; Keigo Komine; Ken Saijo; Masahiro Takahashi; Hidekazu Shirota; Masanobu Takahashi; Makio Gamoh; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2018-03-07       Impact factor: 3.402

6.  Usefulness of the Thrombotic Microangiopathy Score as a Promising Prognostic Marker of Septic Shock for Patients in the Emergency Department.

Authors:  Dong Ryul Ko; Taeyoung Kong; Hye Sun Lee; Sinae Kim; Jong Wook Lee; Hyun Soo Chung; Sung Phil Chung; Je Sung You; Jong Woo Park
Journal:  J Clin Med       Date:  2019-06-06       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.